Displaying drugs 601 - 625 of 757 in total
CM4620
CM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066 (pancreatitis and SIRS), and NCT04661540 (critical COVID-19 pneumonia).
Investigational
8-iodo-guanine
Experimental
(P-Iodophenylacetylamino)Methylphosphinic Acid
Experimental
Iopydol
Experimental
PD150606
Experimental
Rose bengal lactone
Experimental
4-Iodobenzo[B]Thiophene-2-Carboxamidine
Experimental
Caroverine
Experimental
Matched Categories: … Calcium Channel Blockers ... Calcium-Regulating Hormones and Agents …
Tiratricol
A metabolite of T3 and T4 thyroid hormones; promoted for hyperlipidemia, localized lipodystrophy, and obesity. Tiratricol has been used in trials studying the treatment of Allan-Herndon-Dudley Syndrome.
Investigational
Ibacitabine
Experimental
N-Cyclohexyl-N'-(4-Iodophenyl)Urea
Experimental
3,5-diiodothyropropionic acid
DITPA has been investigated in Congestive Heart Failure.
Investigational
t-Butylhydroquinone
Experimental
Matched Categories: … Calcium-Transporting ATPases, antagonists & inhibitors …
Doxofylline
Doxofylline is a methylxanthine derivative with the presence of a dioxolane group in position 7. As a drug used in the treatment of asthma, doxofylline has shown similar efficacy to theophylline but with significantly fewer side effects in animal and human studies. In contrast with other xanthine derivatives, doxofylline does...
Experimental
Matched Description: … Unlike theophylline, doxofylline does not affect calcium influx and does not antagonize the actions of ... calcium channel blockers which could explain reduced cardiac adverse reactions associated with the drug …
Evocalcet
Evocalcet has been used in trials studying the treatment of Hyperparathyroidism and Secondary Hyperparathyroidism.
Investigational
Matched Categories: … Calcium Homeostasis …
Aranidipine
Aranidipine is a novel dihydropyridine derivative that gives rise to two active metabolites (M-1α and M-1β) that exhibit hypotensive activity. It is a calcium antagonist with the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate. It was developed by Maruko Seiyaku, introduced by Taiho and launched in Japan in 1997.
Experimental
Matched Description: … It is a calcium antagonist with the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl …
Matched Categories: … Calcium Channel Blockers …
Matched Categories: … Calcium Channel Blockers …
Tetrandrine
Experimental
Matched Categories: … Calcium Channel Blockers ... Calcium-Regulating Hormones and Agents …
Tolperisone
Tolperisone is an oral, centrally acting muscle relaxant. Its precise mechanism is not completely understood, though it blocks sodium and calcium channels. It possesses a high affinity for nervous system tissue, reaching highest concentrations in brain stem, spinal cord and peripheral nerves. Based on existing clinical data, Tolperisone is not...
Investigational
Matched Description: … Its precise mechanism is not completely understood, though it blocks sodium and calcium channels. …
Eperisone
Eperisone is an antispasmodic drug which relaxes both skeletal muscles and vascular smooth muscles, and demonstrates a variety of effects such as reduction of myotonia, improvement of circulation, and suppression of the pain reflex. It is not approved for use in the United States, but is available in other countries...
Investigational
Matched Categories: … Calcium Channel Blockers ... Calcium-Regulating Hormones and Agents …
Terodiline
Experimental
Matched Categories: … Calcium Channel Blockers ... Calcium-Regulating Hormones and Agents …
2,5-di-tert-butylhydroquinone
Experimental
Matched Categories: … Calcium-Transporting ATPases, antagonists & inhibitors …
5-Iodo-2'-Deoxyuridine-5'-Monophosphate
Experimental
Iodo-Willardiine
Experimental
Displaying drugs 601 - 625 of 757 in total